From: Roles of preoperative C-reactive protein are more relevant in buccal cancer than other subsites
Characteristic | CRP | p value | |||
---|---|---|---|---|---|
Negative | Positive | ||||
Pathologic tumor status | |||||
 Early (T1–T2) (n = 210) | 181 | (86.2%) | 29 | (13.8%) | <0.001 |
 Advanced (T3–T4) (n = 133) | 68 | (51.1%) | 65 | (48.9%) |  |
Pathologic N stage | |||||
 N0 (n = 201) | 156 | (77.6%) | 45 | (22.4%) | 0.006 |
 N1 (n = 47) | 36 | (76.6%) | 11 | (23.4%) | 0.002 a |
 N2 (n = 94) | 57 | (60.6%) | 37 | (39.4%) |  |
 N3 (n = 1) | 0 | (0.0%) | 1 | (100.0%) |  |
Nodal status | |||||
 (−) metastasis, (−) ECS (n = 201) | 156 | (77.6%) | 45 | (22.4%) | 0.006 |
 (+) metastasis, (−) ECS (n = 59) | 44 | (74.6%) | 15 | (25.4%) | 0.002 a |
 (+) metastasis, (+) ECS (n = 83) | 49 | (59.0%) | 34 | (41.0%) |  |
Differentiation | |||||
 Well (n = 107) | 77 | (72.0%) | 30 | (28.0%) | 0.308 |
 Moderate (n = 192) | 144 | (75.0%) | 48 | (25.0%) | 0.538a |
 Poor (n = 44) | 28 | (63.6%) | 16 | (36.4%) |  |
Tumor stage | |||||
 Early (I–II) (n = 142) | 123 | (86.6%) | 19 | (13.4%) | <0.001 |
 Advanced (III–IV) (n = 201) | 126 | (62.7%) | 75 | (37.3%) |  |
Skin invasion | |||||
 No (n = 304) | 231 | (76.0%) | 73 | (24.0%) | <0.001 |
 Yes (n = 39) | 18 | (46.2%) | 21 | (53.8%) |  |
Nerve invasion | |||||
 No (n = 229) | 171 | (74.7%) | 58 | (25.3%) | 0.221 |
 Yes (n = 114) | 78 | (68.4%) | 36 | (31.6%) |  |
Blood vessel invasion | |||||
 No (n = 331) | 242 | (73.1%) | 89 | (26.9%) | 0.322b |
 Yes (n = 12) | 7 | (58.3%) | 5 | (41.7%) |  |
Lymphatic invasion | |||||
 No (n = 334) | 245 | (73.4%) | 89 | (26.6%) | 0.068b |
 Yes (n = 9) | 4 | (44.4%) | 5 | (55.6%) |  |
Tumor depth (≥10 mm) | |||||
 No (n = 160) | 137 | (85.6%) | 23 | (14.4%) | <0.001 |
 Yes (n = 183) | 112 | (61.2%) | 71 | (38.8%) |  |
Bone invasion | |||||
 No (n = 275) | 215 | (78.2%) | 60 | (21.8%) | <0.001 |
 Yes (n = 68) | 34 | (50.0%) | 34 | (50.0%) |  |